Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development
The Pharma Data
NOVEMBER 19, 2020
To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 M pro protease, which plays a crucial role in viral replication 1-4.
Let's personalize your content